Figure 2
From: BRAF inhibition sensitizes melanoma cells to α-amanitin via decreased RNA polymerase II assembly
POLR2A is destabilized by inhibition of oncogenic BRAFV600E signaling. (A) Representative immunoblot of A375-P treated with PLX4720 or DMSO for 48 hours. During the last 16 hours both PLX4720 and DMSO samples were treated with the proteasome inhibitor Bortezomib or vehicle control (n = 3). α-Tubulin served as a loading control. (B) URI1 co-immunoprecipitation of lysates described in (A) (n = 3). (C) Representative immunoblot of A375-P cells treated with PLX4720 or DMSO control for 16 hours, followed by cycoheximide treatment for the indicated timepoints. The lower panel shows the quantification of three independent biological replicates, normalized to the respective 0 CHX timepoint and α-Tubulin loading control (mean ± SD).
